Treatment of mild-to-moderate hypertriglyceridemia

Abstract

The atherogenic role of triglycerides (TG) as an independent cardiovascular risk factor has been discussed for many years, largely because hypertriglyceridaemia (HTG) is a complex metabolic entity of multiple aetiology involving processes of diverse nature. In this chapter, a discussion will be presented on the current recommendations for the management of mild-moderate hypertriglyceridaemia (150-880mg/dL). The aim of the interventions used is to decrease the LDL-cholesterol (c-LDL) and control the HTG. This entails reducing apoprotein B (ApoB) levels, the number of remaining TG-rich lipoproteins (LRP), non-HDL-cholesterol (c-non-HDL), and increasing HDL-cholesterol (c-HDL). The management strategy includes healthy lifestyle recommendations, and subsequent use of lipid-lowering drugs, including statins, fibrates, n-3 fatty acids and PCSK9 inhibitors.

Keywords: ApoB; Colesterol-No HDL; Fibrates; Fibratos; Hipertrigliceridemia leve-moderada; Mild-to-moderate hypertriglyceridaemia; N-3 fatty-acids; Non-HDL-cholesterol; Residual risk; Riesgo residual; Ácidos grasos n-3.